This data is for laboratory research purposes only. Not for human or animal consumption.
What is Survodutide?
Survodutide (BI 456906) is an investigational dual glucagon receptor (GCGR) / GLP-1 receptor (GLP-1R) agonist developed by Boehringer Ingelheim and Zealand Pharma for once-weekly subcutaneous administration. It is the first GCGR/GLP-1R dual agonist to complete Phase 3 trials for obesity.
Mechanism of Action
Survodutide is a 29-amino-acid acylated peptide with a C18 fatty acid half-life extending moiety. It simultaneously activates two G-protein coupled receptors: the GLP-1 receptor, which suppresses appetite and enhances glucose-dependent insulin secretion, and the glucagon receptor, which drives thermogenesis, hepatic fatty acid oxidation, and direct lipolysis. The dual receptor activation provides complementary metabolic effects: GLP-1R agonism reduces caloric intake while GCGR agonism increases energy expenditure and promotes hepatic fat clearance — a mechanism particularly relevant to MASH (metabolic dysfunction-associated steatohepatitis). The peptide incorporates C-terminal amidation and a non-coded amino acid (Ac4c) at position 2 for proteolytic stability.
Observed Laboratory Results
- Phase 3 SYNCHRONIZE-1: 16.6% mean body weight reduction at 76 weeks in adults with obesity without type 2 diabetes versus 3.2% placebo (p<0.0001), meeting both co-primary endpoints.
- ≥5% body weight reduction: Achieved by 85.1% of survodutide-treated participants vs the placebo arm at 76 weeks.
- Phase 2 dose-finding trial: Mean body weight reductions approximately 5-fold greater than placebo at 46 weeks in adults with BMI ≥27 kg/m²; 4.8 mg dose arm demonstrated the most robust efficacy signal.
- MASH regulatory designations: FDA granted Breakthrough Therapy Designation and Fast Track Designation for non-cirrhotic MASH with stage 2–3 fibrosis; EMA granted PRIME designation.